rs144724610
Variant summary
Our verdict is Benign. Variant got -15 ACMG points: 0P and 15B. BP4_ModerateBP6_Very_StrongBP7BS2
The NM_139076.3(ABRAXAS1):c.594C>T(p.His198=) variant causes a splice region, synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000606 in 1,611,062 control chromosomes in the GnomAD database, including 16 homozygotes. In-silico tool predicts a benign outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Benign (★★).
Frequency
Consequence
NM_139076.3 splice_region, synonymous
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -15 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ABRAXAS1 | NM_139076.3 | c.594C>T | p.His198= | splice_region_variant, synonymous_variant | 6/9 | ENST00000321945.12 | NP_620775.2 | |
ABRAXAS1 | NM_001345962.2 | c.267C>T | p.His89= | splice_region_variant, synonymous_variant | 5/8 | NP_001332891.1 | ||
ABRAXAS1 | XR_001741334.3 | n.622C>T | splice_region_variant, non_coding_transcript_exon_variant | 6/9 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ABRAXAS1 | ENST00000321945.12 | c.594C>T | p.His198= | splice_region_variant, synonymous_variant | 6/9 | 1 | NM_139076.3 | ENSP00000369857 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000289 AC: 44AN: 152182Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00123 AC: 308AN: 249468Hom.: 6 AF XY: 0.00160 AC XY: 216AN XY: 134860
GnomAD4 exome AF: 0.000640 AC: 934AN: 1458762Hom.: 16 Cov.: 30 AF XY: 0.000910 AC XY: 660AN XY: 725668
GnomAD4 genome AF: 0.000282 AC: 43AN: 152300Hom.: 0 Cov.: 32 AF XY: 0.000483 AC XY: 36AN XY: 74468
ClinVar
Submissions by phenotype
not specified Benign:1
Benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jun 21, 2021 | Variant summary: FAM175A c.594C>T (p.His198His) alters a conserved nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. 3/4 computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.0012 in 249468 control chromosomes, predominantly at a frequency of 0.0098 within the South Asian subpopulation in the gnomAD database, including 6 homozygotes. The observed variant frequency within South Asian control individuals in the gnomAD database is approximately 314- fold the estimated maximal expected allele frequency for a pathogenic variant in FAM175A causing Hereditary Breast And Ovarian Cancer Syndrome phenotype (3.1e-05), strongly suggesting that the variant is a benign polymorphism found primarily in populations of South Asian origin. To our knowledge, no occurrence of c.594C>T in individuals affected with Hereditary Breast And Ovarian Cancer Syndrome and no experimental evidence demonstrating its impact on protein function have been reported. One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation and cited the variant as benign. Based on the evidence outlined above, the variant was classified as benign. - |
not provided Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 13, 2023 | - - |
ABRAXAS1-related disorder Benign:1
Benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jun 21, 2019 | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at